Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efdelikofusp alfa
- Development stage
- Unknown
- Lead developer
- GI Innovation
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Efdelikofusp alfa (GI-101A) is a novel bispecific immunocytokine designed to enhance anti-tumor immunity by simultaneously targeting the CTLA-4 and IL-2 pathways. It consists of the extracellular domain of human CD80 fused to an engineered interleukin-2 variant (IL-2v2) via an IgG4 Fc linker. The CD80 component acts as a checkpoint inhibitor by binding to CTLA-4 on T cells, thereby blocking immune suppression, and also binds to CD28 to provide co-stimulatory signals. The IL-2v2 component is engineered to have reduced affinity for the high-affinity IL-2 receptor alpha (CD25), which preferentially activates and expands CD8+ T cells and natural killer (NK) cells over immunosuppressive regulatory T cells (Tregs). Developed by GI Innovation, efdelikofusp alfa is being evaluated in clinical trials for the treatment of advanced solid tumors, both as a monotherapy and in combination with other immunotherapies like pembrolizumab.
- Other names
- CD80-IgG4 Fc-IL2v2CD-80-IgG4 Fc-IL2v2CD 80-IgG4 Fc-IL2v2
02
Targets
IL2RG (Interleukin-2 receptor gamma subunit)CD80 (T-lymphocyte activation antigen CD80)IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on efdelikofusp alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efdelikofusp alfa.